Conference abstractPublished 2016
Clobazam: A safe, efficacious, and newly rediscovered therapeutic for Epilepsy
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Clobazam is an oral 1, 5-benzodiazepine used worldwide for the treatment of many types of Epilepsies, although it is currently only approved for LennoxâÂ?Â?Gastaut syndrome in the USA. This anticonvulsant and anxiolytic therapeutic has repeatedly demonstrated great efficacy and a high safety profile in refractory epilepsy as well as in a few monotherapy trials in both children and adults. Clobazam allosterically activates the GABAA receptor, and it binds less to subunits that mediate sedative effects than other benzodiazepines. It acts quickly, maintaining a therapeutic effect for a long duration due to its active metabolite, N-desmethylclobazam. Dosage is between 5 mg and 40 mg a day, depending on patient weight, efficacy, and tolerability. Efficacy tolerance has not been a problem in the best studies. Clobazam has provided many benefits to epileptic patients. It should be used by clinicians early as an adjuvant therapy in the treatment of refractory epilepsy and even considered as monotherapy in a broad spectrum of epilepsy syndromes.
Subjects
Neuroscience & NeurologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. EuroSciCon does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Neuroscience and Neuropharmacology
- SubjectNeuroscience & Neurology
- BylineArticles whose byline prints “Angela Gauthier”
- BylineArticles whose byline prints “Richard Mattson”
